Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 115.61M | 165.96M | 174.19M | 202.71M | 158.41M |
Gross Profit | 20.05M | 18.77M | 38.17M | 58.21M | 58.95M |
EBITDA | -46.49M | -22.02M | -64.65M | -17.04M | -29.62M |
Net Income | -99.67M | -62.38M | -107.46M | -45.12M | -52.11M |
Balance Sheet | |||||
Total Assets | 151.32M | 231.19M | 293.98M | 415.18M | 429.60M |
Cash, Cash Equivalents and Short-Term Investments | 3.00M | 2.03M | 2.20M | 6.95M | 7.43M |
Total Debt | 129.63M | 109.99M | 105.91M | 98.47M | 85.01M |
Total Liabilities | 188.53M | 168.79M | 172.46M | 181.15M | 146.56M |
Stockholders Equity | -37.20M | 62.39M | 121.35M | 233.86M | 283.05M |
Cash Flow | |||||
Free Cash Flow | -1.08M | 4.65M | -6.53M | -12.29M | 7.75M |
Operating Cash Flow | -189.00K | 5.37M | 8.61M | -8.82M | 9.65M |
Investing Cash Flow | -742.00K | 13.17M | -16.84M | 872.00K | -2.52M |
Financing Cash Flow | 1.91M | -18.69M | 4.78M | 6.02M | -2.91M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
71 Outperform | $262.41M | 19.12 | 4.76% | ― | 26.93% | ― | |
63 Neutral | $34.16B | 5.47 | -11.67% | 1.85% | 5.30% | -18.30% | |
58 Neutral | C$188.70M | ― | -38.89% | ― | -6.80% | 11.94% | |
51 Neutral | $344.79M | 105.15 | 3.05% | ― | 26.98% | ― | |
42 Neutral | C$213.77M | ― | -955.11% | ― | -35.53% | -54.28% | |
39 Underperform | $311.50M | ― | -122.10% | ― | -18.39% | 35.21% | |
39 Underperform | $227.80M | ― | -554.70% | ― | -14.45% | 44.87% |
TILT Holdings Inc. reported its financial results for the first quarter of 2025, highlighting a strategic shift towards a more asset-light operating model by divesting plant-touching assets. This move is expected to enhance the company’s scalability and financial performance. The company achieved a significant milestone with the EU medical device certification for its Jupiter handheld liquid vaporizer, indicating a focus on innovation and improved patient care. Despite a decrease in revenue and a net loss, TILT is making progress in repositioning itself in a challenging market environment, with a focus on sustainable growth and margin improvement.
TILT Holdings Inc. reported its first quarter 2025 results, highlighting a strategic shift towards an asset-light, Jupiter-first business model by divesting plant-touching assets. This transition aims to expand market reach and improve financial performance, despite a decrease in revenue and an increased net loss compared to the previous year. The company achieved a significant milestone with the EU certification of its Jupiter QMID vaporizer, enhancing its innovation in medical cannabis delivery.